Tocagen Inc logo

TOCA - Tocagen Inc Share Price

$1.24 -0.1  -4.6%

Last Trade - 7:33pm

Sector
Healthcare
Size
Micro Cap
Market Cap £24.9m
Enterprise Value £11.2m
Revenue £28.9k
Position in Universe 4721st / 6323
Bullish
Bearish
Unlock TOCA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

TOCA Revenue Unlock TOCA Revenue

Net Income

TOCA Net Income Unlock TOCA Revenue

Normalised EPS

TOCA Normalised EPS Unlock TOCA Revenue

PE Ratio Range

TOCA PE Ratio Range Unlock TOCA Revenue

Dividend Yield Range

TOCA Dividend Yield Range Unlock TOCA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TOCA EPS Forecasts Unlock TOCA Revenue
Profile Summary

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated August 24, 2007
Public Since April 13, 2017
No. of Shareholders: 319
No. of Employees: 29
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 23,899,261
Free Float (0.0%)
Eligible for
ISAs
SIPPs
TOCA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for TOCA
Upcoming Events for TOCA
Similar to TOCA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.